Cited by 191Advanced Glycation End Products researchParathyroid Disorders and TreatmentsDermatological and Skeletal Disorders

Advanced Glycation End Products Induce Calcification of Vascular Smooth Muscle Cells through RAGE/p38 MAPK

Tanikawa, Takahisa, Okada, Yosuke, Tanikawa, Rena, Tanaka, Yoshiya·2009·Journal of Vascular Research

Abstract

Background: Mönckeberg’s calcification in diabetes, known as medial artery calcification, is an independent predictor of cardiovascular mortality. However, the mechanism underlying this phenomenon remains to be elucidated. We demonstrate that advanced glycation end products (AGEs) induce calcification of vascular smooth muscle cells through the receptor for AGE (RAGE)/p38 mitogen-activated protein kinase (MAPK) signaling pathway. Methods: We detected vascular calcification by von Kossa staining. Alkaline phosphatase (ALP) activity was determined by measuring p-nitrophenol. Osteocalcin concentrations were measured using ELISA. Western blotting for protein phosphorylation and real-time RT-PCR for expression of mRNA were used. Results: AGEs induced calcification of vascular smooth muscle cells. AGEs also induced the expression of Runx2 mRNA. In addition, AGEs increased ALP activity and osteocalcin secretion. Furthermore, AGEs induced phosphorylation of p38 MAPK, and this phosphorylation was inhibited by the anti-RAGE blocking antibody. Increased ALP activity was inhibited by the p38 MAPK inhibitor or anti-RAGE blocking antibody. Furthermore, the p38 MAPK inhibitor and anti-RAGE blocking antibody both inhibited AGE-induced calcification of vascular smooth muscle cells. Diabetic serum induced calcification of smooth muscle cells and the calcification was inhibited by RAGE blocking. Conclusion: Our findings indicate that AGEs induce calcification of vascular smooth muscle cells by osteoblast-like differentiation of smooth muscle cells through RAGE/p38 MAPK.

Integrity signals

Registry

Crossref · 10.1159/000226225

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Upon binding to their cognate receptor, AGEs trigger activation of downstream effectors including ERK1/2, p38 MAPK, rho-GTPases, JAK, JNK, and NF-kB.

    “Upon binding to their cognate receptor, AGEs trigger the activation of different downstream effectors, including extracellularsignal-regulated kinase 1/2 and p38 mitogen-activated protein kinase, rho-GTPases, Janus kinase, c-Jun N-terminal kinase (JNK), and the transcription factor nuclear-factor-kappa B (NF-𝜅B).[49][50][51][52][53]”

The citation lists haven’t been fetched yet

References 37 · Cited by 191

Authors
Tanikawa, T., Okada, Y., Tanikawa, R., & Tanaka, Y.
Affiliations
University of Occupational and Environmental Health Japan (JP)
Venue
Journal of Vascular Research
Publisher
S. Karger AG
Published
2009
Volume
46
Issue
6
Pages
572-580
ISSN
  • 1018-1172 (ISSN-L)
  • 1423-0135
OpenAlex
W1971886163
Cited by
191
References
37
Citations by year
2026: 4 · 2025: 9 · 2024: 20 · 2023: 9 · 2022: 11 · 2021: 9 · 2020: 10 · 2019: 9 · 2018: 10 · 2017: 16 · 2016: 12 · 2015: 17 · 2014: 12 · 2013: 15 · 2012: 9
FWCI
5.96
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Vascular Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Occupational and Environmental Health
  • Japan Society for the Promotion of Science
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Dermatological and Skeletal Disorders
Keywords
advanced glycation end products, vascular calcification, vascular smooth muscle cells, receptor for advanced glycation end products, p38 MAPK signaling, diabetes mellitus, osteoblast-like differentiation, Runx2, alkaline phosphatase activity, osteocalcin, diabetic serum
MeSH terms
Receptor for Advanced Glycation End Products, Aged, Alkaline Phosphatase, Antibodies, Aorta, Calcinosis, Cells, Cultured, Diabetes Mellitus, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Muscle, Smooth, Vascular, Osteoblasts, Phosphorylation, Receptors, Immunologic, Time Factors, Blotting, Western, Signal Transduction, Osteocalcin, Case-Control Studies, Glycation End Products, Advanced, Reverse Transcriptase Polymerase Chain Reaction, Myocytes, Smooth Muscle, Protein Kinase Inhibitors, p38 Mitogen-Activated Protein Kinases, Core Binding Factor Alpha 1 Subunit, Cell Transdifferentiation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review